Last Updated: November 16, 2026

Investigational Drug Information for AG-348

« Back to Dashboard


What is the development status for investigational drug AG-348?

AG-348 is an investigational drug.

There have been 24 clinical trials for AG-348. The most recent clinical trial was a Phase 3 trial, which was initiated on June 1st 2023.

The most common disease conditions in clinical trials are Anemia, Hemolytic, Pyruvate Metabolism, Inborn Errors, and Anemia, Hemolytic, Congenital Nonspherocytic. The leading clinical trial sponsors are Agios Pharmaceuticals, Inc., National Heart, Lung, and Blood Institute (NHLBI), and National Institutes of Health Clinical Center (CC).

There are fifty-nine US patents protecting this investigational drug and three hundred and seventy-eight international patents.

Recent Clinical Trials for AG-348
TitleSponsorPhase
Safety and Efficacy of Mitapivat Sulfate in Adult Patients With Erythrocyte MembranopathiesEuroBloodNet AssociationPhase 2
A Study to Provide Continued Access to Mitapivat for Participants Who Previously Completed an Agios-Sponsored Mitapivat StudyAgios Pharmaceuticals, Inc.Phase 4
A Pharmacokinetic Study of Mitapivat in Participants With Moderate Hepatic Impairment Compared to Matched Healthy Control Participants With Normal Hepatic FunctionAgios Pharmaceuticals, Inc.Phase 1

See all AG-348 clinical trials

Clinical Trial Summary for AG-348

Top disease conditions for AG-348
Top clinical trial sponsors for AG-348

See all AG-348 clinical trials

US Patents for AG-348

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
AG-348 ⤷  Start Trial Therapeutic compounds and compositions Agios Pharmaceuticals, Inc. (Cambridge, MA) ⤷  Start Trial
AG-348 ⤷  Start Trial Heterocyclic compounds and methods of use Medivation Technologies LLC ⤷  Start Trial
AG-348 ⤷  Start Trial Compounds for the inhibition of indoleamine-2,3-dioxygenase Merck Patent GmbH (Darmstadt, DE) ⤷  Start Trial
AG-348 ⤷  Start Trial Pyruvate kinase activators for use in therapy Agios Pharmaceuticals, Inc. (Cambridge, MA) ⤷  Start Trial
AG-348 ⤷  Start Trial Indole derivative used as CRTH2 inhibitor CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (Lianyungang, CN) ⤷  Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for AG-348

Drugname Country Document Number Estimated Expiration Related US Patent
AG-348 Argentina AR077292 2029-06-29 ⤷  Start Trial
AG-348 Argentina AR112803 2029-06-29 ⤷  Start Trial
AG-348 Australia AU2010266386 2029-06-29 ⤷  Start Trial
AG-348 Brazil BRPI1011587 2029-06-29 ⤷  Start Trial
AG-348 Canada CA2766882 2029-06-29 ⤷  Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

AG-348 Mitapivat Development Update and Market Projection

Last updated: September 9, 2026

AG-348, now marketed as Pyrukynd, is mitapivat, an oral pyruvate kinase activator developed by Agios Pharmaceuticals. The FDA approved it in February 2022 for hemolytic anemia in adults with pyruvate kinase deficiency, a rare inherited red-blood-cell disorder. Agios is expanding development into thalassemia and sickle cell disease, where the addressable population is materially larger than the approved PK-deficiency market.[1]

The commercial outlook depends on three factors: broader indications, sustained reimbursement for a rare-disease oral therapy, and the timing of generic entry after Orange Book patent protection expires. Under a successful thalassemia launch, mitapivat could support annual global revenue above $1 billion. Under a PK-deficiency-only scenario, annual sales are more likely to remain below $500 million.

What is the current FDA status of AG-348 and Pyrukynd?

Pyrukynd is FDA-approved for hemolytic anemia in adults with pyruvate kinase deficiency. The drug is administered orally twice daily, with dose titration based on response and tolerability.[1]

Item Status
Active ingredient Mitapivat
Development code AG-348
Brand Pyrukynd
Sponsor Agios Pharmaceuticals
FDA approval February 17, 2022
Initial indication Hemolytic anemia in adults with pyruvate kinase deficiency
Regulatory pathway New drug application, NDA 216196
Drug type Small-molecule allosteric pyruvate kinase activator
Biosimilar exposure None
Generic exposure Relevant after small-molecule patent and regulatory exclusivity periods

The FDA approval was based principally on ACTIVATE, a randomized Phase 3 trial in adults with pyruvate kinase deficiency who were not regularly transfused. Pyrukynd produced a significantly higher hemoglobin response than placebo. ACTIVATE-T evaluated adults who required regular transfusions and showed a reduction in transfusion burden.[2]

How does mitapivat work?

Mitapivat activates red-blood-cell pyruvate kinase, primarily PKR, an enzyme involved in glycolysis. PKR activation increases ATP production in red blood cells. The mechanism can improve red-cell survival and reduce hemolysis.

The mechanism is relevant beyond PK deficiency. Thalassemia and sickle cell disease involve red-cell stress, ineffective erythropoiesis, anemia, or hemolysis. Mitapivat is being evaluated as a disease-modifying oral therapy rather than as a transfusion-only or supportive-care product.

The principal clinical risks are dose tolerability, loss of response, drug interactions, and the need to establish benefit across genetically and clinically diverse patient populations.

What are the latest development programs for mitapivat?

Thalassemia

Agios has conducted separate Phase 3 studies in non-transfusion-dependent and regularly transfused thalassemia.

The ENERGIZE study evaluated mitapivat in adults with non-transfusion-dependent alpha- or beta-thalassemia. The ENERGIZE-T study evaluated adults with transfusion-dependent thalassemia. Agios reported positive topline results from both studies in 2024, including improvements in hemoglobin response or transfusion reduction, depending on the trial population.[3]

A successful thalassemia filing would expand the market from a very rare PK-deficiency population to a broader inherited-anemia population. The commercial opportunity is strongest in beta-thalassemia, where chronic transfusion, iron overload, chelation therapy, and luspatercept use create a substantial treatment market.

Sickle cell disease

Agios has studied mitapivat in sickle cell disease through the RISE UP program. The program includes adults and adolescents with sickle cell disease and is designed to assess anemia, hemolysis, vaso-occlusive events, and other clinical outcomes.

Sickle cell disease represents the largest potential indication by patient count. It also presents the highest development risk. The competitive market includes hydroxyurea, voxelotor, crizanlizumab, L-glutamine, transfusion, hematopoietic stem-cell transplantation, and emerging gene therapies. Voxelotor's 2024 withdrawal from the market changed the competitive environment, but it did not eliminate the need for robust clinical evidence in sickle cell disease.[4]

Development timeline

Period Event
2019 ACTIVATE and ACTIVATE-T Phase 3 data reported
2022 FDA approved Pyrukynd for adult PK deficiency
2022 European Commission authorization for PK deficiency
2023-2024 Expansion studies in thalassemia and sickle cell disease
2024 Positive topline Phase 3 thalassemia results reported
2024 onward Regulatory preparation and continued sickle-cell development

Regulatory timing for thalassemia depends on the completeness of the filing package, FDA review designation, and the agency's assessment of the clinical data. A thalassemia approval could occur before a sickle-cell approval because the thalassemia Phase 3 program has generated more mature late-stage evidence.

How large is the mitapivat market?

The approved PK-deficiency population is small. Published estimates generally place global PK-deficiency prevalence in the low thousands, although diagnosis rates are incomplete and vary by geography.[5]

A market model based on diagnosed and treated patients produces the following range:

Scenario Treated population Annual net price assumption Potential annual revenue
PK deficiency only 1,000-2,500 $150,000-$220,000 $150 million-$550 million
PK deficiency plus thalassemia 5,000-12,000 $100,000-$180,000 $500 million-$1.8 billion
Broad thalassemia adoption 10,000-20,000 $90,000-$160,000 $900 million-$3.2 billion
Sickle-cell expansion 20,000-50,000 incremental patients $50,000-$120,000 $1 billion-$6 billion incremental

These figures are addressable-market estimates, not reported company guidance. Actual net revenue would be reduced by rebates, government pricing, patient assistance, treatment discontinuation, international pricing, and restrictions from payers.

The most defensible base case is annual global sales of $500 million to $1.2 billion if thalassemia approval is achieved and commercial uptake is sustained. The upper case requires meaningful penetration in sickle cell disease and a price that payers accept relative to existing disease-modifying therapies.

What is the commercial performance of Pyrukynd?

Agios reported rapid early adoption after the 2022 launch, but the product started from a small diagnosed population. Commercial growth depends on finding undiagnosed PK-deficiency patients, increasing genetic testing, and moving eligible patients from transfusion or supportive management to chronic oral treatment.

Key commercial constraints include:

  • Low disease prevalence in the current indication.
  • Limited specialist prescriber base.
  • Need for genetic or enzyme-based diagnosis.
  • Chronic dosing and dose titration.
  • Potential payer controls for rare-disease therapies.
  • Competition from transfusion, chelation, and disease-specific therapies in expanded indications.

Thalassemia offers a clearer commercial path than PK deficiency because patient identification is more established and treatment centers are concentrated. Sickle cell disease offers the greatest volume but also the most complex competitive and clinical environment.

What patents protect mitapivat and Pyrukynd?

Mitapivat is protected by composition-of-matter, pharmaceutical-composition, dosing, and method-of-use patent families. The relevant patent estate originated with Agios and covers substituted pyrazine compounds and their use as pyruvate kinase activators.

The earliest core U.S. composition patent is commonly identified as U.S. Patent No. 9,266,858, with patent-term calculations generally extending into the late 2020s or early 2030s depending on the specific patent and any patent-term adjustment. Later patents may cover dosing regimens, formulations, and treatment of specific diseases.

Protection category Commercial relevance
Composition of matter Primary barrier to generic mitapivat
Pharmaceutical composition May protect tablets, excipients, or dosage forms
Dose escalation and administration May delay label-based generic substitution
PK deficiency methods Protects the approved use
Thalassemia methods Could support indication-specific enforcement
Sickle-cell methods Potential later-expiring use protection
Regulatory exclusivity Provides protection independent of patents

The precise Orange Book listing and expiration date must be assessed patent by patent. Patent-term adjustment, patent-term extension, terminal disclaimers, pediatric exclusivity, and litigation settlements can materially change the effective generic-entry date. FDA Orange Book records are the controlling source for listed patents and exclusivity status.[6]

What is the Orange Book status of Pyrukynd?

Pyrukynd is listed in the FDA Orange Book under NDA 216196. It is a small-molecule product, so it is exposed to an abbreviated new drug application, or ANDA, pathway rather than a biosimilar pathway.

A generic applicant may file a Paragraph IV certification alleging that an Orange Book patent is invalid, unenforceable, or not infringed. If the patent holder sues within the statutory period, FDA approval can be stayed for up to 30 months, subject to court action and statutory exceptions.[7]

There was no widely reported market-shaping Paragraph IV litigation against Pyrukynd through mid-2024. The absence of a public challenge at that stage does not eliminate future risk. Paragraph IV filings typically become more likely as core patent expiration approaches and the commercial opportunity becomes large enough to justify litigation costs.

When could generic mitapivat enter the market?

The earliest practical generic-entry date depends on the strongest enforceable composition patent, any patent-term extension, regulatory exclusivity, and litigation outcomes.

A reasonable scenario range is:

Scenario Potential entry timing Conditions
Early challenge Late 2020s Successful Paragraph IV challenge or noninfringement outcome
Base case Early-to-mid 2030s Core patents remain enforceable until listed expiry
Delayed entry Mid-2030s or later Later method, formulation, or pediatric protection and successful litigation

Generic erosion would likely be gradual in PK deficiency because the patient population is small and treatment is specialist-managed. Erosion could be faster after a thalassemia approval because the market would support more generic competition.

Which companies compete with mitapivat?

Mitapivat has no approved direct PK activator competitor in the United States as of mid-2024. Its broader competitive set varies by indication.

Indication Main alternatives
PK deficiency Transfusion, splenectomy in selected patients, supportive care
Beta-thalassemia Luspatercept, transfusion, iron chelation, stem-cell transplantation
Sickle cell disease Hydroxyurea, crizanlizumab, L-glutamine, transfusion, gene therapies
Hemolytic anemia Disease-specific immunosuppression or supportive therapy, depending on cause

Luspatercept is the most important commercial comparator in thalassemia. It is injectable and acts primarily through erythroid maturation, while mitapivat is an oral metabolic therapy. Their use may be competitive, sequential, or complementary depending on label, payer policy, and clinical response.

What licensing and corporate transactions affect mitapivat?

Agios retained rights to mitapivat after selling its oncology business to Servier in 2020. The Servier transaction did not transfer Pyrukynd's core commercial program. Agios therefore retains the principal economic exposure to U.S. mitapivat sales and to successful expansion into hematologic diseases.[8]

The company could pursue regional partnerships for commercialization, but a large transaction is not required for the base-case model because Agios has an established rare-disease commercial infrastructure.

How strong is the mitapivat patent and market position?

The patent position is strongest for the original molecule and weaker for later indication-specific claims. A composition patent provides broader protection than a method-of-use patent because a generic may face infringement risk even if it markets a narrower label.

The commercial position is strongest in PK deficiency because Pyrukynd is the first approved therapy specifically targeting the underlying red-cell metabolic defect. The position is less secure in thalassemia and sickle cell disease because treatment guidelines, competing mechanisms, and payer restrictions will determine adoption.

The main value inflection point is a thalassemia approval. Sickle-cell data would increase the long-term ceiling but also expose the product to a more competitive market and a higher evidentiary burden.

Key Takeaways

  • AG-348 is mitapivat, marketed in the United States as Pyrukynd.
  • FDA approval covers hemolytic anemia in adults with pyruvate kinase deficiency.
  • Thalassemia is the most commercially advanced expansion opportunity.
  • Sickle cell disease is the largest potential market but carries greater development and competitive risk.
  • A reasonable base-case peak-sales range is $500 million to $1.2 billion globally after a successful thalassemia expansion.
  • Generic entry is unlikely to be commercially meaningful before the late 2020s and may occur in the early-to-mid 2030s, depending on patent litigation and Orange Book protection.
  • There is no biosimilar pathway because mitapivat is a small molecule.
  • Agios retains the principal economic rights to the mitapivat program.

FAQs

Is AG-348 the same drug as Pyrukynd?

Yes. AG-348 is the development code for mitapivat, and Pyrukynd is the commercial brand name.

Is mitapivat approved for thalassemia?

The initial FDA approval was for pyruvate kinase deficiency. Thalassemia approval depends on regulatory review of the Phase 3 ENERGIZE and ENERGIZE-T data.

Does mitapivat compete with luspatercept?

Yes, in thalassemia. Mitapivat is an oral pyruvate kinase activator, while luspatercept is an injectable erythroid-maturation agent. Their relative positioning will depend on indication-specific labels and clinical outcomes.

Can a generic company file an ANDA for Pyrukynd?

Yes. Mitapivat is a small molecule, so generic applicants can use the ANDA pathway and challenge listed patents through Paragraph IV certifications.

What is the biggest risk to the mitapivat market forecast?

The largest risk is failure to convert positive development data into broad regulatory approval and payer coverage in thalassemia or sickle cell disease. The PK-deficiency market alone is unlikely to support the highest revenue projections.

References

  1. U.S. Food and Drug Administration. (2022). FDA approves first drug for anemia in adults with rare inherited blood disorder. https://www.fda.gov
  2. Glenthøj, A., et al. (2022). Mitapivat versus placebo for pyruvate kinase deficiency. New England Journal of Medicine, 386, 1432-1442.
  3. Agios Pharmaceuticals, Inc. (2024). Agios announces positive topline results from Phase 3 ENERGIZE-T study of mitapivat in adults with transfusion-dependent alpha- or beta-thalassemia. https://investor.agios.com
  4. Pfizer Inc. (2024). Pfizer provides update on Oxbryta manufacturing and global voluntary withdrawal. https://www.pfizer.com
  5. Grace, R. F., et al. (2015). The clinical spectrum of pyruvate kinase deficiency: Data from the PK deficiency natural history study. Blood, 126(15), 1772-1779.
  6. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
  7. U.S. Food and Drug Administration. (2024). Hatch-Waxman amendments and abbreviated new drug applications. https://www.fda.gov
  8. Agios Pharmaceuticals, Inc. (2020). Agios and Servier announce closing of transaction for Agios’ oncology business. https://investor.agios.com

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.